US 12,465,586 B2
Inhibitors of glucosylceramide synthase
Hanlan Liu, Lexington, MA (US); Chris Willis, Southborough, MA (US); Renu Bhardwaj, Ashland, MA (US); Jianmei Kochling, Wellesley, MA (US); Judith Peterschmitt, Watertown, MA (US); and Craig Siegel, Woburn, MA (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Jul. 14, 2022, as Appl. No. 17/865,195.
Application 17/865,195 is a division of application No. 13/511,768, granted, now 11,458,119, previously published as PCT/US2010/057952, filed on Nov. 24, 2010.
Claims priority of provisional application 61/264,748, filed on Nov. 27, 2009.
Prior Publication US 2023/0172903 A1, Jun. 8, 2023
Int. Cl. A61K 31/357 (2006.01); A61K 31/4025 (2006.01); A61K 45/06 (2006.01); A61P 3/00 (2006.01); A61P 3/06 (2006.01)
CPC A61K 31/4025 (2013.01) [A61K 31/357 (2013.01); A61K 45/06 (2013.01); A61P 3/00 (2018.01); A61P 3/06 (2018.01)] 7 Claims
 
1. A method of treating a human patient with type 1 Gaucher disease who has been assessed as being a poor CYP2D6 P450 metabolizer as determined by CYP2D6 genotyping, comprising administering to said patient the subject an effective amount of a hemitartrate salt of the compound of formula (I)

OG Complex Work Unit Chemistry
wherein the effective amount is 100 milligrams, wherein the hemitartrate salt of the compound of formula (I) is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from the group consisting of 5.1°, 6.6°, 10.7°, 11.0°, 15.9°, and 21.7°, wherein the specified 2θ angle means the specified value±0.2°, and wherein the X-ray powder diffraction peaks are obtained by using Cu Kα radiation.